Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 3/20 | 0.68 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149886 | 0.83 | ILK (0.63) | ILKPARP10MEN1KMT2ANPC1 | |
| SCHEMBL5147749 | 0.79 | ILK (0.68) | ILKPARP10MEN1KMT2ANPC1 | |
| SCHEMBL5147923 | 0.77 | ILK (0.77) | ILKMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5149415 | 0.74 | ILK (0.73) | ILKMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5146319 | 0.72 | ILK (0.73) | ILKMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL4598560 | 0.71 | LTA4H (0.75) | PARP10LTA4HMEN1KMT2ANPC1 | |
| SCHEMBL5146290 | 0.70 | ILK (0.66) | ILKMEN1KMT2ARAB9A | |
| SCHEMBL11714868 | 0.70 | MEN1 (0.67) | SIRT2LTA4HMEN1KMT2ANPC1 | |
| SCHEMBL4667938 | 0.70 | LTA4H (0.64) | SIRT2PARP10LTA4HNPC1RAB9A | |
| SCHEMBL5147557 | 0.70 | ILK (0.74) | ILKMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288556-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7022702-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | DERMIRA (CANADA), INC. | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND1, CCND3 | ILK 1286/4885SIRT2 1886/4885PARP10 1121/4885 |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND3, ACIN1 | ILK 2862/4885SIRT2 1046/4885PARP10 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.